MinervaX
Clinical-stage biotechnology company developing a Group B Streptococcus (GBS) vaccine to prevent life-threatening infections in newborns through maternal immunization.
Website
https://www.minervax.comLocation
Copenhagen, Denmark
Founded
2010
Investors
1
Categories
vaccines, infectious-disease, maternal-health, biotech, neonatal
Notes
MinervaX is a clinical-stage biotechnology company focused on developing a vaccine against Group B Streptococcus (GBS), a leading cause of life-threatening infections in newborns worldwide. The company's maternal vaccine, GBS-NN, is designed to be given to pregnant women to protect their babies through passive antibody transfer.
GBS infections can cause sepsis, meningitis, and pneumonia in newborns, with significant mortality and long-term disability. MinervaX's vaccine aims to prevent these devastating outcomes by immunizing expectant mothers.
Team
- Per Fischer - Chief Executive Officer
- LinkedIn: linkedin.com/in/perfischer
Additional Research Findings
- Founded in 2010
- Headquarters in Copenhagen, Denmark
- Lead candidate GBS-NN in clinical development
- Maternal vaccination approach for newborn protection
- Group B Strep causes ~150,000 newborn deaths annually
- Orphan drug designations in US and EU
- Backed by specialist life sciences investors
- Addresses major unmet need in maternal-infant health
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Adjuvant Capital | Washington, DC, USA | biotech-focused | seedseries-a+3 | 16 |